deaths (OS)progression or deaths (PFS)RFS/DFS

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus docetaxel
pembrolizumab (10mg/kg) vs. docetaxel 2 low degree of certaintystatistically conclusive-39% low degree of certaintystatistically conclusive-28%-
pembrolizumab (2mg/kg) vs. docetaxel 2 low degree of certaintystatistically conclusive-33% low degree of certainty-25%-